We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

100 hedge funds and large institutions have $739M invested in Avidity Biosciences in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

258% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 12

225% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 8

22% more funds holding

Funds holding: 82 → 100 (+18)

7.65% more ownership

Funds ownership: 82.5% → 90.15% (+7.7%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less capital invested

Capital invested by funds: $790M → $739M (-$51.3M)

Holders
100
Holders Change
+18
Holders Change %
+21.95%
% of All Funds
1.76%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
26
Increased
43
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$19.9M
2
State Street
State Street
Massachusetts
+$16.3M
3
BlackRock
BlackRock
New York
+$16.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$11.5M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$9.03M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$17.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.52M
3
ACM
Alethea Capital Management
Washington
-$4.54M
4
TG
TCW Group
California
-$4.13M
5
ACP
Acuta Capital Partners
California
-$4.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Altium Capital Management
New York
$3.9M +$4.37M +178,600 New
Morgan Stanley
27
Morgan Stanley
New York
$3.41M +$2.19M +89,317 +133%
Charles Schwab
28
Charles Schwab
California
$3.13M +$830K +33,902 +31%
AG
29
Artal Group
Luxembourg
$3.11M – – –
WP
30
Woodline Partners
California
$2.79M – – –
SCM
31
Soleus Capital Management
Connecticut
$2.38M +$2.67M +109,130 New
N
32
Nuveen
North Carolina
$2.1M +$761K +31,104 +48%
Millennium Management
33
Millennium Management
New York
$2.03M -$272K -11,120 -11%
Wells Fargo
34
Wells Fargo
California
$1.9M +$155K +6,317 +8%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.84M +$518K +21,177 +33%
ACP
36
Acuta Capital Partners
California
$1.79M -$4.02M -164,200 -67%
Citigroup
37
Citigroup
New York
$1.67M +$1.75M +71,383 +1,393%
Los Angeles Capital Management
38
Los Angeles Capital Management
California
$1.45M +$44.7K +1,826 +3%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$1.32M +$1.49M +60,704 New
RJA
40
Raymond James & Associates
Florida
$1.08M +$1.22M +49,643 New
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$1M +$506K +20,676 +82%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$743K +$834K +34,070 New
NL
43
NWAM LLC
Washington
$696K +$781K +31,921 New
HS
44
HighVista Strategies
Massachusetts
$693K +$126K +5,132 +19%
Bank of America
45
Bank of America
North Carolina
$691K +$442K +18,051 +133%
UBS Group
46
UBS Group
Switzerland
$673K +$709K +28,979 +1,528%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$666K +$275K +11,214 +58%
SG Americas Securities
48
SG Americas Securities
New York
$666K +$747K +30,534 New
Swiss National Bank
49
Swiss National Bank
Switzerland
$648K – – –
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$646K -$66.6K -2,720 -8%
1
2
3 4 5

RNAM Hedge Fund Activity: Q1 2021 in Review

100 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2021, worth a combined $739M — down 6.5% from $790M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new RNAM positions and 8 closed out — a net gain of 18 holders — while 43 added to existing stakes and 12 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $19.9M. The largest seller was Logos Global Management, exiting entirely with an estimated $17.1M sold.

  • 100 institutional investors held Avidity Biosciences (RNAM) as of Q1 2021, up from 82 in Q4 2020.
  • Funds reported $739M of Avidity Biosciences stock for Q1 2021, down 6.5% quarter-over-quarter.
  • 26 funds opened new Avidity Biosciences positions in Q1 2021 and 8 closed out, a net change of +18 holders.
  • The largest Avidity Biosciences buyer in Q1 2021 was T. Rowe Price Associates, an estimated $19.9M added.
  • The largest Avidity Biosciences seller in Q1 2021 was Logos Global Management, an estimated $17.1M sold.

Based on aggregated 13F filings for Q1 2021.